Alternative splicing within the Wnt signaling pathway: role in cancer development

Cellular Oncology

Volumn 39, Issue 1, 2016, Pages 1-13

  Sumithra, B ^a   Saxena, Urmila ^a   Das, Asim Bikas ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Alternative splicing; Cancer; Isoforms; mRNA; Proliferation; Splicing factor; Wnt signaling; catenin

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; CASEIN KINASE I; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; GROUCHO PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; RNA; TRANSCRIPTION FACTOR; TRANSDUCING LIKE ENHANCER OF SPLIT PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; LIGAND;

ALTERNATIVE RNA SPLICING; CANCER GROWTH; CARCINOGENESIS; HUMAN; MOLECULAR PATHOLOGY; NEOPLASM; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY; BIOLOGICAL MODEL; GENETICS; METABOLISM; PATHOLOGY;

ALTERNATIVE SPLICING; CARCINOGENESIS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84954316173     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0266-0     Document Type: Review

References (150)

1. H. Clevers, Wnt/beta-catenin signaling in development and disease. Cell 127, 469–480 (2006)
2. R. Nusse, WNT targets. repression and activation. Trends Genet. 15, 1–3 (1999)
3. W. Zhang, H.T. Liu, MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12, 9–18 (2002)
4. A.J. Whitmarsh, Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim. Biophys. Acta 1773, 1285–1298 (2007)
5. M.J. Fan, W. Gruning, G. Walz, S.Y. Sokol, Wnt signaling and transcriptional control of Siamois in Xenopus embryos. Proc. Natl. Acad. Sci. U. S. A. 95, 5626–5631 (1998)
6. F. Heyd, K.W. Lynch, Degrade, move, regroup: signaling control of splicing proteins. Trends Biochem. Sci. 36, 397–404 (2011)
7. K.W. Lynch, Regulation of alternative splicing by signal transduction pathways. Adv. Exp. Med. Biol. 623, 161–174 (2007)
8. M. Blaustein, F. Pelisch, A. Srebrow, Signals, pathways and splicing regulation. Int. J. Biochem. Cell Biol. 39, 2031–2048 (2007)
9. G.S. Martin, Cell signaling and cancer. Cancer Cell 4, 167–74 (2003)
10. S. Oltean, D.O. Bates, Hallmarks of alternative splicing in cancer. Oncogene 33, 5311–5318 (2014)
11. W.-Y. Tarn, Cellular signals modulate alternative splicing. J. Biomed. Sci. 14, 517–522 (2007)
12. C. Ghigna, C. Valacca, G. Biamonti, Alternative splicing and tumor progression. Curr. Genomics 9, 556–570 (2008)
13. S. Germann, L. Gratadou, M. Dutertre, D. Auboeuf, Splicing programs and cancer. J. Nucleic Acids 2012, 269570 (2012)
14. B.M. Brinkman, Splice variants as cancer biomarkers. Clin. Biochem. 37, 584–594 (2004)
15. P.M. Lizardi, M. Forloni, N. Wajapeyee, Genome-wide approaches for cancer gene discovery. Trends Biotechnol. 29, 558–568 (2011)
16. J.P. Venables, Aberrant and alternative splicing in cancer. Cancer Res. 64, 7647–7654 (2004)
17. P.J. Gardina, T.A. Clark, B. Shimada, M.K. Staples, Q. Yang, J. Veitch, A. Schweitzer, T. Awad, C. Sugnet, S. Dee, C. Davies, A. Williams, Y. Turpaz, Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 7, 325 (2006)
18. R. van Amerongen, R. Nusse, Towards an integrated view of Wnt signaling in development. Development 136, 3205–3214 (2009)
19. H. Clevers, R. Nusse, Wnt/beta-catenin signaling and disease. Cell 149, 1192–1205 (2012)
20. R. Nusse, C. Fuerer, W. Ching, K. Harnish, C. Logan, A. Zeng, D. Ten Berge, Y. Kalani, Wnt signaling and stem cell control. Cold Spring Harb. Symp. Quant. Biol. 73, 59–66 (2008)
21. Y. Xi, Y. Chen, Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis. Cancer Lett. 353, 8–16 (2014)
22. H. Clevers, Wnt breakers in colon cancer. Cancer Cell 5, 5–6 (2004)
23. C.H. Lin, T. Ji, C.F. Chen, B.H. Hoang, Wnt signaling in osteosarcoma. Adv. Exp. Med. Biol. 804, 33–45 (2014)
24. T. Reya, H. Clevers, Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005)
25. V. Goncalves, P. Matos, P. Jordan, The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression. RNA 14, 2538–2549 (2008)
26. B.T. MacDonald, K. Tamai, X. He, Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009)
27. J.L. Stamos, W.I. Weis, The beta-catenin destruction complex. Cold Spring Harb. Perspect. Biol. 5, a007898 (2013)
28. C. Niehrs, The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 13, 767–779 (2012)
29. V.S. Li, S.S. Ng, P.J. Boersema, T.Y. Low, W.R. Karthaus, J.P. Gerlach, S. Mohammed, A.J. Heck, M.M. Maurice, T. Mahmoudi, H. Clevers, Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149, 1245–1256 (2012)
30. T.C. He, A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, P.J. Morin, B. Vogelstein, K.W. Kinzler, Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512 (1998)
31. M. Shtutman, J. Zhurinsky, I. Simcha, C. Albanese, M. D’Amico, R. Pestell, A. Ben-Ze’ev, The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U. S. A. 96, 5522–5527 (1999)
32. E.H. Jho, T. Zhang, C. Domon, C.K. Joo, J.N. Freund, F. Costantini, Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 22, 1172–1183 (2002)
33. V.J. Wielenga, R. Smits, V. Korinek, L. Smit, M. Kielman, R. Fodde, H. Clevers, S.T. Pals, Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154, 515–523 (1999)
34. B. Mann, M. Gelos, A. Siedow, M.L. Hanski, A. Gratchev, M. Ilyas, W.F. Bodmer, M.P. Moyer, E.O. Riecken, H.J. Buhr, C. Hanski, Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 96, 1603–1608 (1999)
35. S.P. Rockman, S.A. Currie, M. Ciavarella, E. Vincan, C. Dow, R.J. Thomas, W.A. Phillips, Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J. Biol. Chem. 276, 45113–45119 (2001)
36. J. Willert, M. Epping, J.R. Pollack, P.O. Brown, R. Nusse, A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev. Biol. 2, 8 (2002)
37. M. Fujita, Y. Furukawa, T. Tsunoda, T. Tanaka, M. Ogawa, Y. Nakamura, Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res. 61, 7722–7726 (2001)
38. T. Brabletz, A. Jung, S. Dag, F. Hlubek, T. Kirchner, Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155, 1033–1038 (1999)
39. J.R. Miller, The Wnts. Genome Biol. 3, REVIEWS3001 (2002)
40. M. Katoh, H. Kirikoshi, T. Saitoh, N. Sagara, J. Koike, Alternative splicing of the WNT-2B/WNT-13 gene. Biochem. Biophys. Res. Commun. 275, 209–216 (2000)
41. I.T. Struewing, A. Toborek, C.D. Mao, Mitochondrial and nuclear forms of Wnt13 are generated via alternative promoters, alternative RNA splicing, and alternative translation start sites. J. Biol. Chem. 281, 7282–7293 (2006)
42. M. Katoh, H. Kirikoshi, H. Terasaki, K. Shiokawa, WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT- beta-catenin-TCF signaling pathway. Biochem. Biophys. Res. Commun. 289, 1093–1098 (2001)
43. R.P. Bunaciu, T. Tang, C.D. Mao, Differential expression of Wnt13 isoforms during leukemic cell differentiation. Oncol. Rep. 20, 195–201 (2008)
44. M.W. Fear, D.P. Kelsell, N.K. Spurr, M.R. Barnes, Wnt-16a, a novel Wnt-16 isoform, which shows differential expression in adult human tissues. Biochem. Biophys. Res. Commun. 278, 814–820 (2000)
45. J. Mazieres, L. You, B. He, Z. Xu, A.Y. Lee, I. Mikami, F. McCormick, D.M. Jablons, Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene 24, 5396–5400 (2005)
46. A. Memarian, P. Vosough, H. Asgarian-Omran, M. Tabrizi, M. Shabani, F. Shokri, Differential WNT gene expression in various subtypes of acute lymphoblastic leukemia. Iran J. Immunol. 9, 61–71 (2012)
47. M.T. Teh, D. Blaydon, L.R. Ghali, V. Briggs, S. Edmunds, E. Pantazi, M.R. Barnes, I.M. Leigh, D.P. Kelsell, M.P. Philpott, Role for WNT16B in human epidermal keratinocyte proliferation and differentiation. J. Cell Sci. 120, 330–339 (2007)
48. M. Bauer, J. Benard, T. Gaasterland, K. Willert, D. Cappellen, WNT5A encodes two isoforms with distinct functions in cancers. PLoS One 8, e80526 (2013)
49. A.T. Weeraratna, Y. Jiang, G. Hostetter, K. Rosenblatt, P. Duray, M. Bittner, J.M. Trent, Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279–288 (2002)
50. P.D. Da Forno, J.H. Pringle, P. Hutchinson, J. Osborn, Q. Huang, L. Potter, R.A. Hancox, A. Fletcher, G.S. Saldanha, WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 14, 5825–5832 (2008)
51. M. Kurayoshi, N. Oue, H. Yamamoto, M. Kishida, A. Inoue, T. Asahara, W. Yasui, A. Kikuchi, Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66, 10439–10448 (2006)
52. S. Ripka, A. Konig, M. Buchholz, M. Wagner, B. Sipos, G. Kloppel, J. Downward, T. Gress, P. Michl, WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28, 1178–1187 (2007)
53. H. Liang, Q. Chen, A.H. Coles, S.J. Anderson, G. Pihan, A. Bradley, R. Gerstein, R. Jurecic, S.N. Jones, Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4, 349–360 (2003)
54. J. Ying, H. Li, Y.W. Chen, G. Srivastava, Z. Gao, Q. Tao, WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood 110, 4130–4132 (2007)
55. J. Ying, H. Li, J. Yu, K.M. Ng, F.F. Poon, S.C. Wong, A.T. Chan, J.J. Sung, Q. Tao, Clin. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin. Cancer Res. 14, 55–61 (2008)
56. L. Bi, X. Liu, C. Wang, Y. Cao, R. Mao, P. Li, M. Geng, Wnt5a involved in regulation of the biological behavior of hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 7, 987–995 (2014)
57. A.V. Posviatenko, K.V. Kulikova, N.V. Gnuchev, G.P. Georgiev, A.V. Kibardin, S.S. Larin, Functional properties of the WNT11 new isoform, expressed in colon carcinoma cell line HT29. Mol. Biol. 46, 129–138 (2012)
58. M. Kuhl, L.C. Sheldahl, M. Park, J.R. Miller, R.T. Moon, The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 16, 279–283 (2000)
59. A.J. Mikels, R. Nusse, Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 4, e115 (2006)
60. G. Schulte, International union of basic and clinical pharmacology. LXXX. the class Frizzled receptors. Pharmacol. Rev. 62, 632–667 (2010)
61. J.P. Dijksterhuis, J. Petersen, G. Schulte, WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3. Br. J. Pharmacol. 171, 1195–1209 (2014)
62. D.T. Bravo, Y.L. Yang, K. Kuchenbecker, M.S. Hung, Z. Xu, D.M. Jablons, L. You, Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer 13, 316 (2013)
63. T.D. King, M.J. Suto, Y. Li, The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J. Cell. Biochem. 113, 13–18 (2012)
64. R.F. Holcombe, J.L. Marsh, M.L. Waterman, F. Lin, T. Milovanovic, T. Truong, Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol. Pathol. 55, 220–226 (2002)
65. X. Jin, H.Y. Jeon, K.M. Joo, J.K. Kim, J. Jin, S.H. Kim, B.G. Kang, S. Beck, S.J. Lee, J.K. Kim, A.K. Park, W.Y. Park, Y.J. Choi, D.H. Nam, H. Kim, Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 71, 3066–3075 (2011)
66. N. Sagara, H. Kirikoshi, H. Terasaki, Y. Yasuhiko, G. Toda, K. Shiokawa, M. Katoh, FZD4S, a splicing variant of frizzled-4, encodes a soluble-type positive regulator of the WNT signaling pathway. Biochem. Biophys. Res. Commun. 282, 750–756 (2001)
67. S. Narumi, C. Numakura, T. Shiihara, C. Seiwa, Y. Nozaki, T. Yamagata, M.Y. Momoi, Y. Watanabe, M. Yoshino, T. Matsuishi, E. Nishi, H. Kawame, T. Akahane, G. Nishimura, M. Emi, T. Hasegawa, Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. Am. J. Med. Genet. A 152A, 133–140 (2010)
68. E.R. Barros, M.R. Dias da Silva, I.S. Kunii, O.M. Hauache, M. Lazaretti-Castro, A novel mutation in the LRP5 gene is associated with osteoporosis-pseudoglioma syndrome. Osteoporos. Int. 18, 1017–1018 (2007)
69. S.A. Rabbani, A. Arakelian, R. Farookhi, LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2, 625–635 (2013)
70. B.H. Hoang, Wnt, osteosarcoma, and future therapy. J. Am. Acad. Orthop. Surg. 20, 58–59 (2012)
71. H. Pospisil, A. Herrmann, K. Butherus, S. Pirson, J.G. Reich, W. Kemmner, Verification of predicted alternatively spliced Wnt genes reveals two new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression during tumour progression. BMC Genomics 7, 148 (2006)
72. P. Bjorklund, G. Akerstrom, G. Westin, An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med. 4, e328 (2007)
73. P. Bjorklund, J. Svedlund, A.K. Olsson, G. Akerstrom, G. Westin, The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One 4, e4243 (2009)
74. J. Green, R. Nusse, R. van Amerongen, The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. Cold Spring Harb.Perspect. Biol. 6pii, a009175 (2014)
75. S. Baskar, K.Y. Kwong, T. Hofer, J.M. Levy, M.G. Kennedy, E. Lee, L.M. Staudt, W.H. Wilson, A. Wiestner, C. Rader, Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14, 396–404 (2008)
76. H. Dave, M.R. Anver, D.O. Butcher, P. Brown, J. Khan, A.S. Wayne, S. Baskar, C. Rader, Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One 7, e52655 (2012)
77. M. Hojjat-Farsangi, A.S. Khan, A.H. Daneshmanesh, A. Moshfegh, A. Sandin, L. Mansouri, M. Palma, J. Lundin, A. Osterborg, H. Mellstedt, The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One 8, e78339 (2013)
78. U.R. Reddy, S. Phatak, D. Pleasure, Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene 13, 1555–1559 (1996)
79. H.C. Tseng, H.W. Kao, M.R. Ho, Y.R. Chen, T.W. Lin, P.C. Lyu, W.C. Lin, Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res. 31, 4239–4249 (2011)
80. A.H. Daneshmanesh, M. Hojjat-Farsangi, A.S. Khan, M. Jeddi-Tehrani, M.M. Akhondi, A.A. Bayat, R. Ghods, A.R. Mahmoudi, R. Hadavi, A. Osterborg, F. Shokri, H. Rabbani, H. Mellstedt, Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 26, 1348–1355 (2012)
81. N. Borcherding, D. Kusner, G.H. Liu, W. Zhang, ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5, 496–502 (2014)
82. X. Song, S. Wang, L. Li, New insights into the regulation of Axin function in canonical Wnt signaling pathway. Protein Cell 5, 186–193 (2014)
83. H. Clevers, Axin and hepatocellular carcinomas. Nat. Genet. 24, 206–208 (2000)
84. N. Parveen, M.U. Hussain, A.A. Pandith, S. Mudassar, Diversity of axin in signaling pathways and its relation to colorectal cancer. Med. Oncol. 28(Suppl 1), S259–267 (2011)
85. C.X. Zhou, Y. Gao, Frequent genetic alterations and reduced expression of the Axin1 gene in oral squamous cell carcinoma: involvement in tumor progression and metastasis. Oncol. Rep. 17, 73–79 (2007)
86. S. Salahshor, J.R. Woodgett, The links between axin and carcinogenesis. J. Clin. Pathol. 58, 225–236 (2005)
87. X. Zhang, A.S. Farrell, C.J. Daniel, H. Arnold, C. Scanlan, B.J. Laraway, M. Janghorban, L. Lum, D. Chen, M. Troxell, R. Sears, Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc. Natl. Acad. Sci. U. S. A. 109, 2790–2795 (2012)
88. S. Satoh, Y. Daigo, Y. Furukawa, T. Kato, N. Miwa, T. Nishiwaki, T. Kawasoe, H. Ishiguro, M. Fujita, T. Tokino, Y. Sasaki, S. Imaoka, M. Murata, T. Shimano, Y. Yamaoka, Y. Nakamura, AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24, 245–250 (2000)
89. D.Y. Dao, X. Yang, D. Chen, M. Zuscik, R.J. O’Keefe, Axin1 and Axin2 are regulated by TGF- and mediate cross-talk between TGF- and Wnt signaling pathways. Ann. N. Y. Acad. Sci. 1116, 82–99 (2007)
90. Y. Zhang, S.Y. Neo, X. Wang, J. Han, S.C. Lin, Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J. Biol. Chem. 274, 35247–35254 (1999)
91. K. Aoki, M.M. Taketo, Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J. Cell Sci. 120, 3327–3335 (2007)
92. K. Furuuchi, M. Tada, H. Yamada, A. Kataoka, N. Furuuchi, J. Hamada, M. Takahashi, S. Todo, T. Moriuchi, Somatic mutations of the APC gene in primary breast cancers. Am. J. Pathol. 156, 1997–2005 (2000)
93. A.H. Nakatsuru, Y. Miyoshi, S. Ichii, H. Nagase, H. Ando, A. Yanagisawa, E. Tsuchiya, Y. Kato, Y. Nakamura, Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res. 52, 6696–6698 (1992)
94. A.H. Nakatsuru, Y. Miyoshi, S. Ichii, H. Nagase, Y. Kato, A. Yanagisawa, Y. Nakamura, The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res. 52, 3231–3233 (1992)
95. S.M. Powell, N. Papadopoulos, K.W. Kinzler, K.N. Smolinski, S.J. Meltzer, APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 107, 1759–1763 (1994)
96. G.S. Charames, H. Cheng, C.A. Gilpin, A.G. Hunter, T. Berk, B. Bapat, A novel aberrant splice site mutation in the APC gene. J. Med. Genet. 39, 754–757 (2002)
97. S.H. Chandra, I. Wacker, U.K. Appelt, J. Behrens, J. Schneikert, A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation. PLoS One 7, e34479 (2012)
98. T.M. Tuohy, M.W. Done, M.S. Lewandowski, P.M. Shires, D.S. Saraiya, S.C. Huang, D.W. Neklason, R.W. Burt, Large intron 14 rearrangement in APC results in splice defect and attenuated FAP. Hum. Genet. 127, 359–369 (2010)
99. V. Goncalves, P. Theisen, O. Antunes, A. Medeira, J.S. Ramos, P. Jordan, G. Isidro, A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat. Res. 662, 33–36 (2009)
100. S. Aretz, S. Uhlhaas, Y. Sun, C. Pagenstecher, E. Mangold, R. Caspari, G. Moslein, K. Schulmann, P. Propping, W. Friedl, Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum. Mutat. 24, 370–380 (2004)
101. D.W. Neklason, C.H. Solomon, A.L. Dalton, S.K. Kuwada, R.W. Burt, Intron 4 mutation in APC gene results in splice defect and attenuated FAP phenotype. Fam. Cancer 3, 35–40 (2004)
102. H. Kurahashi, K. Takami, T. Oue, T. Kusafuka, A. Okada, A. Tawa, S. Okada, I. Nishisho, Biallelic inactivation of the APC gene in hepatoblastoma. Cancer Res. 55, 5007–5011 (1995)
103. A. Kaufmann, S. Vogt, S. Uhlhaas, D. Stienen, I. Kurth, H. Hameister, E. Mangold, J. Kotting, E. Kaminsky, P. Propping, W. Friedl, S. Aretz, Analysis of rare APC variants at the mRNA level: six pathogenic mutations and literature review. J. Mol. Diagn. 11, 131–139 (2009)
104. K. Miyashita, M. Nakada, A. Shakoori, Y. Ishigaki, T. Shimasaki, Y. Motoo, K. Kawakami, T. Minamoto, An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med. Chem. 9, 1114–1122 (2009)
105. J. Luo, Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273, 194–200 (2009)
106. J.A. McCubrey, L.S. Steelman, F.E. Bertrand, N.M. Davis, M. Sokolosky, S.L. Abrams, G. Montalto, A.B. D’Assoro, M. Libra, F. Nicoletti, R. Maestro, J. Basecke, D. Rakus, A. Gizak, Z.N. Demidenko, L. Cocco, A.M. Martelli, M. Cervello, GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5, 2881–2911 (2014)
107. A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, I.G. Newton, F.J. Giles, J. Durocher, R.S. Creusot, M. Karimi, C. Jones, J.L. Zehnder, A. Keating, R.S. Negrin, I.L. Weissman, C.H. Jamieson, Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 106, 3925–3929 (2009)
108. V. Goncalves, P. Matos, P. Jordan, Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum. Mol. Genet. 18, 3696–3707 (2009)
109. V. Goncalves, A. Henriques, J. Pereira, A. Neves Costa, M.P. Moyer, L.F. Moita, M. Gama-Carvalho, P. Matos, P. Jordan, Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA 20, 474–482 (2014)
110. K. Thorsen, F. Mansilla, T. Schepeler, B. Oster, M.H. Rasmussen, L. Dyrskjot, R. Karni, M. Akerman, A.R. Krainer, S. Laurberg, C.L. Andersen, T.F. Orntoft, Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol. Cell. Proteomics 10, M110.002998 (2011)
111. B. Schittek, T. Sinnberg, Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Mol. Cancer 13, 231 (2014)
112. T. Sinnberg, M. Menzel, D. Ewerth, B. Sauer, M. Schwarz, M. Schaller, C. Garbe, B. Schittek, Beta-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 6, e23429 (2011)
113. T. Maritzen, J. Lohler, W. Deppert, U. Knippschild, Casein kinase I delta (CKIdelta) is involved in lymphocyte physiology. Eur. J. Cell Biol. 82, 369–378 (2003)
114. M. Stoter, A.M. Bamberger, B. Aslan, M. Kurth, D. Speidel, T. Loning, H.G. Frank, P. Kaufmann, J. Lohler, D. Henne-Bruns, W. Deppert, U. Knippschild, Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells. Oncogene 24, 7964–7975 (2005)
115. C. Brockschmidt, H. Hirner, N. Huber, T. Eismann, A. Hillenbrand, G. Giamas, B. Radunsky, O. Ammerpohl, B. Bohm, D. Henne-Bruns, H. Kalthoff, F. Leithauser, A. Trauzold, U. Knippschild, Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Gut 57, 799–806 (2008)
116. S.Y. Kim, I.F. Dunn, R. Firestein, P. Gupta, L. Wardwell, K. Repich, A.C. Schinzel, B. Wittner, S.J. Silver, D.E. Root, J.S. Boehm, S. Ramaswamy, E.S. Lander, W.C. Hahn, CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One 5, e8979 (2010)
117. S.H. Lin, Y.M. Lin, C.M. Yeh, C.J. Chen, M.W. Chen, H.F. Hung, K.T. Yeh, S.F. Yang, Casein kinase 1 epsilon expression predicts poorer prognosis in low T-stage oral cancer patients. Int. J. Mol. Sci. 15, 2876–2891 (2014)
118. R. Nusse, Wnt signaling. Cold Spring Harb. Perspect. Biol. 4, a011163 (2012)
119. A. Thiele, Y. Nagamine, S. Hauschildt, H. Clevers, AU-rich elements and alternative splicing in the beta-catenin 3′UTR can influence the human beta-catenin mRNA stability. Exp. Cell Res. 312, 2367–2378 (2006)
120. F. Nollet, G. Berx, F. Molemans, F. van Roy, Genomic organization of the human beta-catenin gene (CTNNB1). Genomics 32, 413–424 (1996)
121. M.J. Roth, N. Hu, L.L. Johnson, W. Quon-Hang, D.J. Ahnen, M. Iwamoto, S.M. Dawsey, P.R. Taylor, K. Huppi, Beta-Catenin splice variants and downstream targets as markers for neoplastic progression of esophageal cancer. Genes Chrom. Cancer 44, 423–428 (2005)
122. A.N. Brooks, P.S. Choi, L. de Waal, T. Sharifnia, M. Imielinski, G. Saksena, C.S. Pedamallu, A. Sivachenko, M. Rosenberg, J. Chmielecki, M.S. Lawrence, D.S. DeLuca, G. Getz, M. Meyerson, A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One 9, e87361 (2014)
123. J. Stockley, M.E. Villasevil, C. Nixon, I. Ahmad, H.Y. Leung, P. Rajan, The RNA-binding protein hnRNPA2 regulates beta-catenin protein expression and is overexpressed in prostate cancer. RNA Biol. 11, 755–765 (2014)
124. K.I. Takemaru, M. Ohmitsu, F.Q. Li, An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. Handb. Exp. Pharmacol. 261–284 (2008)
125. H.K. Lee, Y.S. Choi, Y.A. Park, S. Jeong, Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells. Cancer Res. 66, 10560–10566 (2006)
126. S. Sato, M. Idogawa, K. Honda, G. Fujii, H. Kawashima, K. Takekuma, A. Hoshika, S. Hirohashi, T. Yamada, Beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. Gastroenterology 129, 1225–1236 (2005)
127. A. Herbst, V. Jurinovic, S. Krebs, S.E. Thieme, H. Blum, B. Goke, F.T. Kolligs, Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics 15, 74 (2014)
128. L. Arce, K.T. Pate, M.L. Waterman, Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression. BMC Cancer 9, 159 (2009)
129. D.L. Daniels, W.I. Weis, Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat. Struct. Mol. Biol. 12, 364–371 (2005)
130. B.H. Jennings, D. Ish-Horowicz, The Groucho/TLE/Grg family of transcriptional co-repressors. Genome Biol. 9, 205 (2008)
131. H.I. Nakaya, F.C. Beckedorff, M.L. Baldini, A.A. Fachel, E.M. Reis, S. Verjovski-Almeida, Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors. Biochem. Biophys. Res. Commun. 364, 918–923 (2007)
132. P.C. Chen, M. Kuraguchi, J. Velasquez, Y. Wang, K. Yang, R. Edwards, D. Gillen, W. Edelmann, R. Kucherlapati, S.M. Lipkin, Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. PLoS Genet. 4, e1000092 (2008)
133. S. Hoppler, C.L. Kavanagh, Wnt signalling: variety at the core. J. Cell Sci. 120, 385–393 (2007)
134. K. Hovanes, T.W. Li, J.E. Munguia, T. Truong, T. Milovanovic, J. Lawrence Marsh, R.F. Holcombe, M.L. Waterman, Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat. Genet. 28, 53–57 (2001)
135. A. Ravindranath, A. O’Connell, P.G. Johnston, M.K. El-Tanani, The role of LEF/TCF factors in neoplastic transformation. Curr. Mol. Med. 8, 38–50 (2008)
136. C. Mosimann, G. Hausmann, K. Basler, Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat. Rev. Mol. Cell Biol. 10, 276–286 (2009)
137. L. Arce, N.N. Yokoyama, M.L. Waterman, Diversity of LEF/TCF action in development and disease. Oncogene 25, 7492–7504 (2006)
138. B. Wallmen, M. Schrempp, A. Hecht, Intrinsic properties of Tcf1 and Tcf4 splice variants determine cell-type-specific Wnt/beta-catenin target gene expression. Nucleic Acids Res. 40, 9455–9469 (2012)
139. M. Shitashige, S. Hirohashi, T. Yamada, Wnt signaling inside the nucleus. Cancer Sci. 99, 631–637 (2008)
140. A. Weise, K. Bruser, S. Elfert, B. Wallmen, Y. Wittel, S. Wohrle, A. Hecht, Alternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at Wnt/beta-catenin targets. Nucleic Acids Res. 38, 1964–1981 (2010)
141. N.P. Hoverter, M.D. Zeller, M.M. McQuade, A. Garibaldi, A. Busch, E.M. Selwan, K.J. Hertel, P. Baldi, M.L. Waterman, The TCF C-clamp DNA binding domain expands the Wnt transcriptome via alternative target recognition. Nucleic Acids Res. 42, 13615–13632 (2014)
142. F.A. Atcha, A. Syed, B. Wu, N.P. Hoverter, N.N. Yokoyama, J.H. Ting, J.E. Munguia, H.J. Mangalam, J.L. Marsh, M.L. Waterman, A unique DNA binding domain converts T-cell factors into strong Wnt effectors. Mol. Cell. Biol. 27(8352–8363) (2007)
143. M.L. Angus-Hill, K.M. Elbert, J. Hidalgo, M.R. Capecchi, T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 108, 4914–4919 (2011)
144. F. Liu, O. van den Broek, O. Destree, S. Hoppler, Distinct roles for Xenopus Tcf/Lef genes in mediating specific responses to Wnt/beta-catenin signalling in mesoderm development. Development 132, 5375–5385 (2005)
145. O. Tsedensodnom, H. Koga, S.A. Rosenberg, S.B. Nambotin, J.J. Carroll, J.R. Wands, M. Kim, Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp. Cell Res. 317, 920–931 (2011)
146. T. Vacik, G. Lemke, Dominant-negative isoforms of Tcf/Lef proteins in development and disease. Cell Cycle 10, 4199–4200 (2011)
147. T.W. Li, J.H. Ting, N.N. Yokoyama, A. Bernstein, M. van de Wetering, M.L. Waterman, Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol. Cell. Biol. 26, 5284–5299 (2006)
148. S.H. Wang, K.J. Nan, Y.C. Wang, W.J. Wang, T. Tian, The balance between two isoforms of LEF-1 regulates colon carcinoma growth. BMC Gastroenterol. 12, 53 (2012)
149. N. Takebe, L. Miele, P.J. Harris, W. Jeong, H. Bando, M. Kahn, S.X. Yang, S.P. Ivy, Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445–464 (2015)
150. M. Kahn, Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 13, 513–532 (2014)